Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1487677

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1487677

Carboprost Tromethamine Market - By Application (Postpartum Hemorrhage Treatment, Pregnancy Abortion), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Forecast (2024 - 2032)

PUBLISHED:
PAGES: 130 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 5350
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

Carboprost tromethamine market is anticipated to grow at 7.9% CAGR from 2024 to 2032, driven by the increasing prevalence of conditions, such as postpartum hemorrhage (PPH) and uterine atony, particularly in developing regions. As per WHO, annually, around 14 million women endure postpartum hemorrhage (PPH), leading to roughly 70,000 maternal fatalities worldwide. These conditions pose significant risks to maternal health during childbirth, necessitating effective interventions to control bleeding and prevent complications. Advancements in obstetric care and rising awareness among healthcare professionals about the efficacy in managing PPH is fueling the adoption of carboprost tromethamine in clinical settings.

The treatment of gynecological disorders like menstrual disorders and incomplete abortion will further spur the market expansion. As healthcare providers seek versatile treatment options to address a range of reproductive health issues, the demand for carboprost tromethamine is rising. Furthermore, favorable government initiatives are improving maternal healthcare infrastructure and reducing maternal mortality rates, particularly in emerging economies.

The carboprost tromethamine industry is segmented into application, distribution channel and region.

The market share from pregnancy abortion application segment is anticipated to gain momentum and grow at 8%CAGR through 2032. Carboprost tromethamine is widely recognized as an effective uterotonic agent for inducing uterine contractions and facilitating the expulsion of fetal tissue during medical abortion procedures. With the increasing acceptance and availability of medical abortion as a safe and non-invasive alternative to surgical procedures, the growing demand for pharmacological agents to support the process will add to the segment growth.

As per distribution channel, the carboprost tromethamine market value from the online pharmacies segment is poised to witness 6.8% growth rate over the forecast period. The convenience and accessibility offered by online pharmacies makes it easier for healthcare providers to procure essential medications like carboprost tromethamine, particularly in regions with limited access to traditional brick-and-mortar pharmacies. The availability of a wide range of pharmaceutical products on online pharmacies also enables healthcare professionals to conveniently source carboprost tromethamine along with other medications for streamlining the procurement processes.

Asia Pacific carboprost tromethamine industry size will record notable expansion at 8.5% CAGR between 2024 and 2032, attributed to the high burden of maternal mortality rates, particularly in countries with limited access to obstetric care. The increasing adoption of medical abortion procedures and expanding access to reproductive healthcare services are contributing to the rising product demand. Supportive government initiatives aimed at improving maternal and reproductive healthcare infrastructure, along with higher healthcare expenditure and awareness will further fuel the regional market growth.

Product Code: 8526

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of postpartum hemorrhage
      • 3.2.1.2 Increasing initiatives by government and various organizations
      • 3.2.1.3 Rising publicly funded family planning services
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Lack of awareness among rural population
      • 3.2.2.2 Adverse effects associated with use of contraceptive drugs and devices
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Postpartum hemorrhage treatment
  • 5.3 Pregnancy abortion

Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hospital pharmacies
  • 6.3 Retail pharmacies
  • 6.4 Online pharmacies

Chapter 7 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
    • 7.5.4 Rest of Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 South Africa
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

  • 8.1 Advancion Corporation
  • 8.2 Amneal Pharmaceuticals, Inc.
  • 8.3 Apionex Pharma Pvt Ltd.
  • 8.4 Biosynth Limited
  • 8.5 Bio-Techne Corporation
  • 8.6 BioSpectra Inc.
  • 8.7 Dr. Reddy's Laboratories Ltd.
  • 8.8 Merck & Co., Inc.
  • 8.9 Monvi Laboratories Private Limited
  • 8.10 Manus Aktteva Biopharma Llp
  • 8.11 Pfizer Inc.
  • 8.12 Ryvis Pharma Private Limited
  • 8.13 SimSon Pharma Limited
  • 8.14 Taj Pharmaceuticals Limited
  • 8.15 The International Chemical Secretariat
  • 8.16 Universal Biosensors, Inc.
  • 8.17 Willis Towers Watson Public Limited Company
  • 8.18 Woodward, Inc.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!